Prialt (ziconotide acetate) NDC 68118-723

NDC codes

FDA NDC Directory

Product NDC (as listed)68118-723Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68118-0723Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68118-723-10	68118072310	1 VIAL, GLASS in 1 CARTON (68118-723-10) / 20 mL in 1 VIAL, GLASSMarketed from Aug 15, 2019

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Prialt
Generic name (nonproprietary): ziconotide acetate
Active ingredients: Ziconotide acetate — 500 ug/20mL
Dosage form: Injection, Solution
Route: Intrathecal
Labeler: ESTEVE PHARMACEUTICALS, S.A.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021060
Marketing start: Oct 15, 2018
Listing expires: Dec 31, 2027
Other FDA classes: N-Calcium Channel Receptor Antagonists (Mechanism)
Identifiers: Product ID 68118-723_57e9b601-e657-b5ef-e063-6394a90af39fSPL ID 57e9b601-e657-b5ef-e063-6394a90af39fSPL set ID 57376a5b-4530-9018-e063-6394a90a9afeRxCUI 486133, 583453, 1738353, 1738354, 1738357, 1738358UNII T2I226K69M
Pharmacologic class: N-type Calcium Channel Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N468118072310 followed by a unit qualifier and the quantity

Package 68118-0723-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021060

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021060
Product	Strength	Form · route	Labeler	Product NDC
Prialtziconotide acetate	Ziconotide acetate 500 ug/5mL	Injection, SolutionIntrathecal	ESTEVE PHARMACEUTICALS, S.A.	68118-722
Prialtziconotide acetate	Ziconotide acetate 100 ug/mL	Injection, SolutionIntrathecal	ESTEVE PHARMACEUTICALS, S.A.	68118-720
Prialtziconotide acetate	Ziconotide acetate 25 ug/mL	Injection, SolutionIntrathecal	TerSera Therapeutics LLC	70720-723
Prialtziconotide acetate	Ziconotide acetate 100 ug/mL	Injection, SolutionIntrathecal	TerSera Therapeutics LLC	70720-720
Prialtziconotide acetate	Ziconotide acetate 100 ug/mL	Injection, SolutionIntrathecal	TerSera Therapeutics LLC	70720-722